Biotech

Tyme Technologies (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, announced that Mack Roach III, M.D., FASTRO, FACR, Professor of Radiation Oncology, Medical Oncology and Urology at the University of California, San Francisco (UCSF), will lead one or more investigator-initiated trials to evaluate SM-88 therapy in prostate cancer. As quoted in the press release: “A …

Tyme Technologies (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, announced that Mack Roach III, M.D., FASTRO, FACR, Professor of Radiation Oncology, Medical Oncology and Urology at the University of California, San Francisco (UCSF), will lead one or more investigator-initiated trials to evaluate SM-88 therapy in prostate cancer.
As quoted in the press release:

“A spectrum of patients including those suitable for Active Surveillance (AS) to those with high-risk and relapsing prostate cancer face a number of difficult choices concerning their disease. In some, it is whether to delay treatment and be followed with AS, waiting for symptomatic progression, or be aggressive by initiating potentially toxic treatment as soon as possible,” said Dr. Roach.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20181.92+80.54
TSXV705.58+14.41
DOW31253.13-236.94
S&P 5003900.79-22.89
NASD11388.50-29.66
ASX7064.50-118.20

COMMODITIES

Commodities
Gold1846.19+4.01
Silver22.04+0.14
Copper4.32+0.03
Palladium2016.50+12.50
Platinum969.00+10.00
Oil111.94-0.27
Heating Oil3.670.00
Natural Gas8.06-0.25

DOWNLOAD FREE REPORTS

×